US 11,872,267 B2
Treatment of uterine fibroids using purified collagenase
James H. Segars, Baltimore, MD (US); Phyllis Carolyn Leppert, Salt Lake City, UT (US); Thomas L. Wegman, N. Merrick, NY (US); and Jean-Marie Soma, Lynbrook, NY (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US); Duke University, Durham, NC (US); and BioSpecifics Technologies LLC, Malvern, PA (US)
Filed by The Johns Hopkins University, Baltimore, MD (US); Duke University, Durham, NC (US); and BioSpecifics Technologies LLC, Malvern, PA (US)
Filed on Oct. 14, 2020, as Appl. No. 17/070,747.
Claims priority of provisional application 62/915,360, filed on Oct. 15, 2019.
Prior Publication US 2021/0113670 A1, Apr. 22, 2021
Int. Cl. A61K 38/48 (2006.01); A61P 15/00 (2006.01); A61K 9/00 (2006.01); A61B 5/00 (2006.01)
CPC A61K 38/4886 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 9/0034 (2013.01); A61P 15/00 (2018.01); A61B 5/4824 (2013.01); C12Y 304/24003 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method for reducing the size of a uterine fibroid in a patient, the method comprising:
administering into the uterine fibroid a composition comprising Clostridium histolyticum collagenase I and collagenase II in a 1:1 mass ratio to thereby reduce the size of the uterine fibroid, wherein there is an at least two fold increase in LC3B expression within the uterine fibroid as measured at 60 days following the administration.